# Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

Source: https://onco.cc/trials/nct06642545/  
OnCo record `nct06642545` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Disitamab vedotin, RC148 and Toripalimab in HER2-positive breast cancer, run by RemeGen Co., Ltd., now recruiting.

## Summary

Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer is a phase 2 interventional study registered as NCT06642545 by RemeGen Co., Ltd., with 40 participants planned, started 2025-02-10 and due to reach its primary completion in 2026-10-01. Interventions recorded: Disitamab Vedotin, RC148, Albumin-bound Paclitaxone and Toripalimab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06642545
- Phase: 2
- Setting: A Randomized, Open-label, Controlled, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With RC148 Versus Albumin-bound Paclitaxone Alone or in Combination With Toripalimab in Subjects With HR-negative, HER2-low Expressing Unresectable Locally Advanced or Metastatic Breast Cancer
- Sponsor: RemeGen Co., Ltd.
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT06642545: https://clinicaltrials.gov/study/NCT06642545

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [Disitamab vedotin](https://onco.cc/drugs/disitamab-vedotin/), [RC148](https://onco.cc/drugs/rc148/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- companies: [RemeGen](https://onco.cc/companies/remegen/)

---
JSON: https://onco.cc/api/v1/entities/nct06642545.json